1. Introduction
===============

Cure rates for advanced ovarian cancer are low, regardless of the type of treatment received. An average 5-year survival rate of 10% (0-15%) has been obtained with abdominal radiation therapy [@B1]-[@B4], and response rates vary from 3 to 30% with chemotherapy [@B5]-[@B9]. Recent multivariate analyses of prognostic factors suggest that the size of the residual tumor after first surgery is the most important variable in predicting the response to therapy [@B3]; for each 10% increase in maximum cytoreduction, survival increased by 5.5%. There was an average difference in survival of approximately 11 months between the less-than-25% and the greater-than-75% maximum cytoreduction cohorts [@B10].

The use of Cisplatin, which presents encouraging response rates, is associated with longer survival [@B11]; however, often the efficacy of highly aggressive regimens is only seen in those patients with highly favorable prognostic factors (optimal cytoreductive surgery). According to the Goldie-Coldman theory, early administration of aggressive regimens could selectively interfere with the number of drug-resistant cells arising by spontaneous mutation, reducing them to a minimum [@B1] and therefore possibly neutralizing the risk of relapse. The relapse rate for epithelial ovarian carcinoma in pathologic Complete Remission is generally between 42 and 44% [@B12]-[@B14]. Abdominal radiotherapy as consolidation treatment produced forms of gastrointestinal toxicity, such as subocclusion and enteritis, without significant therapeutic advantage [@B15]-[@B17].

In early ovarian cancer, adjuvant chemotherapy is effective [@B18]; Trimbos et. al. reported results from a randomized trial, one conducted by the EORTC (European Organisation for Research and Treatment of Cancer) (ACTION Study) where immediate chemotherapy significantly improved recurrence-free survival with an absolute difference at five years of 8%, but with a greater advantage found among patients having had non-optimal staging or surgical treatment at inexperienced centers.

However, other randomized studies have shown that disease-free survival and overall survival in advanced ovarian cancer do not vary in relation to the number of cycles of chemotherapy given, (6 vs. 9 cycles of PAC \[Platinum-Adriamycin-Cyclophosphamide\] [@B19], 5 vs. 10 cycles of polychemotherapy with Cisplatin [@B20], 6 vs. 12 cycles of PAC [@B21] or 5 vs. 8 courses of platinum [@B22]), while still other trials on a small number of patients with absent disease or residuum \<2cm (table [1](#T1){ref-type="table"}) would seem to confirm the usefulness of radiotherapy or of chemoradiotherapy as consolidation [@B23].

2. Patients and Methods
=======================

From October 1988 to October 1996, 122 patients affected by epithelial ovarian cancer who had been found to be in complete remission, as judged by laparoscopy and/or laparotomy, entered the GOCCNE study (Gruppo Oncologico Cooperativo Clinico del Nord-Est, consisting of 20 centers in North-east Italy) designed to evaluate the usefulness of consolidation chemotherapy in patients with pathologic complete remission. First-line chemotherapy consisted of Anthracyclin-Cyclophosphamide for 54 patients, Mitoxantrone-Carboplatin for 5 elderly patients and Cyclophosphamide-Platinum for 63 patients. Pathologic complete remission was assessed by CT scan in all patients; if this was negative, the same patients underwent laparoscopic control. All patients with negative laparotomy (70 pts; however, 1 pt. after a negative laparoscopy, at time of randomization resulted positive at second look laparotomy performed autonomously) and/or negative laparoscopic second looks (52 pts) were proposed for the study and randomly assigned to consolidation chemotherapy with 5-Fluorouracil + Cisplatin or nihil.

Inclusion in the study was based on a histologically documented diagnosis, completion of first-line chemotherapy and a performance status higher than 60. In addition, it was required that patients have normal renal function (creatinine \<2 mg/dL, BUN \<45 mmol/L), hepatic function (conjugated bilirubin \<2 mg/dL, ALP \<150 U/L and γGT \<80 U/L) and cardiac function (as judged by physical examination, measurement of pulse and arterial pressure and ECG). Patients were also required to give their informed consent.

Patients over 80 years of age were excluded, as were patients with WBC counts \<4000/mm^3^ or platelets \<140,000/mm^3^. Patients presenting with second tumors, psychiatric disorders, brain metastases and those with altered ECGs, suggesting important conduction disturbances (dromotropic or bathmotropic), were also excluded.

Consolidation chemotherapy with 5-Fluorouracil (5-FU) and Cisplatin consisted of 5-FU 500 mg/m^2^/day intravenously for 5 days, followed by Cisplatin at a dose of 100 mg/m^2^ on the 6^th^ or 7^th^ day (never exceeding a total dose of 160 mg) associated with Allopurinol 300 mg/day. This was repeated every 28 days for 3 cycles. The choice of 5-Fluorouracil was based on the fact that 5-FU had been shown to be highly effective in salvage therapy for refractory ovarian cancer patients with low bulk disease [@B24], [@B25].

In cases developing arterial hypertension or myocardiosclerosis (with diastolic pressure \>120mmHg) during treatment, the dose of 5-FU was reduced by 25%. The first day of 5-FU was abolished in cases of myelotoxicity protracted from the previous cycle (more than 5 weeks to recovery). Cisplatin was reduced by 50% in mononephric patients, or when obstructive nephropathy was encountered, as well as in cases of important hypacusia or neurotoxicity or in patients over 76 years of age.

Statistical comparison of overall and disease-free survival was based on Kaplan-Meier estimates of survival and a log-rank test of statistical significance.

3. Results
==========

The study population consisted of 122 patients. Median age of both the consolidation therapy population and the nihil arm was 55 (range: 38-76 and 16-73, respectively). The stage distribution was 15 pts stage I C, 30 pts stage II B and II C, 71 pts stage III, and 5 pts stage IV; histologic grade was grade 1 in 19 cases, 2 in 45 cases and 3 in 57 cases. Distribution of histological grade for the Cisplatin arm vs. the nihil arm was grade 1-2 in 30 vs. 34 cases and grade 3 in 30 vs. 27 cases. Characteristics of the two groups can be found in table [2](#T2){ref-type="table"}.

The 61 patients in the nihil arm completed 5 cycles of first-line chemotherapy only, while an additional 3 cycles of polychemotherapy with FU followed by Cisplatin were proposed for the 61 patients in the Cisplatin arm. Of the 61 patients assigned to the Cisplatin arm, 47 (77.0%) completed 3 or more cycles. However, 4 patients (6.6%) completed only 1 cycle while 9 patients (14.8%) completed 2 cycles before suspending treatment (for noncompliance or for excessive gastrointestinal and/or neurological toxicity). One patient (1.6%) refused treatment entirely after randomization and is therefore not evaluable. Three of the 47 patients who completed 3 cycles continued treatment even further, receiving an additional 1-3 cycles of Cisplatin for a total of 4-6 cycles (table [2](#T2){ref-type="table"}).

The toxicity in treatment with Cisplatin consisted of nausea and vomiting in 38 patients (62.3% of Cisplatin-treated patients); this was WHO grade 3 in 17 pts (27.9%) and grade 4 in 10 pts (16.4%); it was neurological in 21 pts (34.4%), and consisted of leukopenia in 13 pts (21.3%), mucositis in 7 pts (11.5%), nephrotoxicity in 4 pts (6.6%), infection in 3 (4.9%) and anemia in another 2 (3.3%) pts (table [3](#T3){ref-type="table"}).

The overall survival of the two groups was very similar (fig.[1](#F1){ref-type="fig"}.). There were 36 relapses (59.0%) in the Cisplatin arm and 30 (49.2%) in the "nihil" arm. Peritoneal relapses varied for the two arms and were 15 (25%) for Cisplatin vs. 10 (16.4%) for nihil. Relapses in the vaginal dome were found in 1 case (1.7%) treated with Cisplatin and 5 (8.2%) in the nihil arm, while hepatic and splenic relapses were nearly identical. Relapses in lung-pleura were also similar: 5 (8.3%) in the Cisplatin arm vs. 6 (9.8%) in the nihil arm. Relapses in lumboaortic-inguinal lymph nodes were 11 (18.0%) in the Cisplatin arm and 4 (6.6%) in the nihil arm (table [4](#T4){ref-type="table"}).

Seven patients presented a second neoplasm after treatment for ovarian cancer. There were two cases of breast cancer, two cases of sigmoid adenocarcinoma, one case of small cell lung cancer, one case of hypernephroma, and one case of head and neck cancer. Six of these patients were in the nihil arm. Only one patient (head and neck cancer) was in the Cisplatin arm. Death in these patients resulted from the second neoplasm and not from progression of ovarian cancer.

Median overall survival was 87 months for the cisplatin arm (82.0% at 3 years) and 89 months for the nihil arm (80.3% at 3 years) (p=0.66, log rank test). Median disease free survival was 68 months (range 1.4-170.0) for the Cisplatin arm (62.1% at three years for the cisplatin arm) and 73 months (range 1.6-169.5) for the nihil arm (62.3% at three years for the nihil arm). There was no statistical difference between the two groups (p=0.41, log rank test).

4. Discussion
=============

Ovarian cancer patients have high response rates to initial chemotherapy after cytoreductive surgery. There are fewer complete responses with the use of anthracyclin and alkylating agents as first-line treatment, although their duration is greater than the complete responses obtained by platinum chemotherapy [@B5]. Relapses occur in 30% of the cases within the first 3 years [@B26]. It is thus possible that the use of alkylating agents and anthracyclins could select responders who have a different prognosis from patients treated with a platinum-based regime. Unlike Gershenson [@B27] who sustains the usefulness of prolonged chemotherapy with platinum, other investigators have found that prolonging chemotherapy does not have any benefit in terms of survival [@B19]-[@B22].

In the literature there is no agreement regarding treatment of patients with ovarian cancer who are in complete remission following first-line chemotherapy, and no therapeutic modality shows a clear and definite advantage in terms of disease-free survival. Moreover, there are no large comparative randomized studies on this topic [@B19]-[@B21], [@B26].

In 1988 when the present trial was proposed there was uncertainty as to whether 3 additional courses of platinum based chemotherapy were useful in patients who had obtained complete remission after 5 courses of first-line chemotherapy with or without Cisplatin. The choice of Cisplatin + 5-FU was based on the fact that other drugs such liposomal Doxorubicin, Paclitaxel, or Topotecan were not available at that time.

Radiation therapy was not chosen for consolidation treatment because the literature provided no studies to support a significant advantage over chemotherapy [@B26], [@B28], [@B29] while presenting local toxicity. Still, Pickle et al. [@B23], in a randomized study, demonstrated the usefulness of radiation therapy in association with chemotherapy in patients (predominantly stage III) who were judged free of disease, after radical surgery and six cycles of first-line chemotherapy, with respect to thirty-two patients who received only whole abdominal radiation following surgery. The overall and relapse-free survival was better for the group receiving combination chemo-radiotherapy, confirming the fundamental role of systemic treatment.

Our experience with only 121 evaluable patients, however, suggests that there is no difference between chemotherapeutic consolidation after remission vs. nihil. This trial therefore seems to confirm the findings of other authors, namely that the 5-year-survival of patients without residual tumor mass following first surgery varies between 50 and 70% [@B3], [@B30], and that their survival is better than that of patients with residual mass \<2 cm (which varies between 35-55%) or patients with residuum of 2 cm or more (which varies between 0-30%) [@B3], [@B7].

While statistical analysis of the present study does not note any significant difference in overall survival (fig. [1](#F1){ref-type="fig"}) or in disease-free survival (fig. [2](#F2){ref-type="fig"}) between the two arms suggesting that polychemotherapy with cisplatin is not very effective in a consolidative setting, it is limited by the lack of stratification by stage, and by previous type of chemotherapy (table [2](#T2){ref-type="table"}) as well as by the limited number of patients randomized (122 pts). The lack of stratification might have resulted in the selection of a population with better prognostic factors in the nihil arm vs. the Cisplatin arm, thereby creating a bias; thus, this result should be evaluated with caution

It is worth noting that many of our patients had not been previously treated with platinum, and yet survival rates were similar to those for patients with platinum based first-line therapy. This would seem to cast doubts on the long-term efficacy of platinum therapy in ovarian cancer.

In our study severe toxicity was rare with the exception of grade 3-4 emesis encountered in 44,3%. Severe nausea was controlled in most of the patients; however, in 21.3% of patients toxicity was severe enough to suspend treatment either for non-compliance or for excessive gastrointestinal toxicity, thus cycles were suspended in 13 patients (4 after completing only one cycle, while 9 refused further treatment after completing the second cycle). Our patients did not experience severe neuropathy. In addition, severe events such as sepsis or hematologic toxicity were also uncommon in our study with the exception of 1 case of grade 4 thrombocytopenia.

Oddly, there were more relapses in lumboaortic-inguinal lymph nodes in the chemotherapy arm, however, in this study the different distribution of patients with regard to residuum and stage, which resulted from a lack of stratification, might have produced a lack of benefit in terms of recurrence and survival.

Currently, tumor cell heterogeneity and clonal selection of resistant tumor cells continue to be major obstacles in cancer therapy. *In vitro* experimental studies are limited in that they cannot represent the heterogeneity of cancer cells observed *in vivo*. On the other hand, some immunohistochemical correlation with clinical aspects of disease is starting to emerge [@B31], [@B32], [@B33], [@B34] and may eventually provide clues for further tailoring of therapy to the specific patient. In addition, in programming new therapeutic approaches it is necessary to understand the percentage of relapses after complete remission that are due to residual tumor cells and how many might be due to a perpetuation of carcinogenesis in the peritoneal cavity. To date, the most important variable in survival of patients with epithelial ovarian cancer is residual disease \> 10 cm after first surgery; these patients present with an extremely high relapse rate. Thus, "wait and see" is still the main choice for patients who have reached complete remission after first-line chemotherapy in the absence of confirmatory data from randomized trials.
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###### 

Studies of efficacy of consolidation treatment in ovarian cancer

  Study               Year                     N. pts.   Stage            Treatment             Residuum before consolidation                                                     Efficacy                       
  ------------------- ------------------------ --------- ---------------- --------------------- --------------------------------------------------------------------------------- ------------------------------ -----------------------------------------------
  1\.                 Falcone [@B35]           1988      16               IIB-IV                WAR                                                                               Microscopic disease (10 pts)   Slight advantage for microscopic disease
  \< 2 cm (6 pts)                                                                                                                                                                                                
  2\.                 Nicoletto [@B36]         1992      18               IIIA-B                i.p. αIFN x 4 to CCR + 4 cycles consolidation                                     Microscopic disease (11 pts)   Possibly effective in microscopic disease
  \< 2 cm (7 pts)                                                                                                                                                                                                
  3\.                 Menczer [@B28], [@B29]   1989      37               II-IV                 i.p. cisplatin x 3                                                                                               i.p. cisplatin might be better than RT
  WAR                                                                                                                                                                                                            
  1995                21                                 i.p. cisplatin   CCR 17 SL (10+; 7-)   i.p. cisplatin+etoposide does not seem more effective than i.p. cisplatin alone                                  
  4\.                 Bruzzone [@B33]          1997      111                                    JM8 400 i.p.                                                                                                     αIFN does not improve D.F. or O.S.
  αIFN+JM8 400 i.p.                                                                                                                                                                                              
  5\.                 Barakat [@B37]           1998      36               IIC-IV                i.p. cisplatin VP 16 x 3                                                          Microscopic disease (13 pts)   i.p. cisplatin improved disease-free survival
  Nihil                                                                                                                                                                                                          
  6\.                 Pickel [@B23]            1999      64                                     32 pts - WAR                                                                                                     RT offers promising results
  32 pts - nihil                                                                                                                                                                                                 

WAR= whole abdominal radiation; RT = radiotherapy; nihil = no treatment; D.F.= median disease-free survival; O.S.= median overall survival; i.p. = intraperitoneal; CCR= complete clinical remission; JM8 = Carboplatin; αIFN = interferon α; SL = second look

###### 

Patient characteristics

  Characteristics   Cisplatin (n=60 pts)                            Nihil (n=61 pts)   
  ----------------- ----------------------------------------------- ------------------ ------------
  **1.**            **Median Age (years)**                          55                 55
                    Range                                           38-76              16-73
  **2.**            **Stage (FIGO)**                                                   
                    IC                                              3 (4.9%)           12 (19.7%)
                    IIB-C                                           13 (21.3%)         17 (27.9%)
                    IIIA-B-C + IV                                   45 (73.8%)         32 (52.4%)
  **3.**            **Histological Type**                                              
                    Serous Papillary                                45 (73.8%)         32 (52.5%)
                    Undifferentiated                                3 (4.9%)           6 (9.8%)
                    Clear Cell                                      2 (3.3%)           2 (3.3%)
                    Endometrioid                                    8 (13.1%)          15 (24.6%)
                    Mucinous                                        \-                 4 (6.6%)
                    Mixed                                           3 (4.9%)           2 (3.3%)
  **4.**            **Histological Grade**                                             
                    1-2                                             30 (49.2%)         34 (55.7%)
                    3                                               31 (50.8%)         27 (44.3%)
  **5.**            **Type of first line chemotherapy**                                
                    Anthracyclin-Cyclophosphamide                   30 (49.2%)         24 (39.3%)
                    Mitoxantrone-Cisplatin                          2 (3.3%)           3 (4.9%)
                    Cyclophosphamide-Cisplatin                      29 (47.5%)         34 (55.7%)
  **6.**            **Type of Surgery**                                                
                    Laparoscopy                                     **-**              1 (1.6%)
                    Tumor Reduction                                 13 (21.3%)         5 (8.2%)
                    Radical Surgery                                 48 (78.7%)         55 (90.2%)
  **7.**            **PostsurgicalResidual Disease (first look)**                      
                    Residuum ≤2 cm                                  51 (83.6%)         55 (90.2%)
                    Residuum \>2 cm                                 10 (16.4%)         6 (9.8%)
  **8.**            Total number of cycles completed                                   
                    0                                               1 (%)              **-**
                    1                                               4 (%)              **-**
                    2                                               9 (%)              **-**
                    3                                               44 (%)             **-**
                    4                                               2 (%)              **-**
                    5                                               **-**              **-**
                    6                                               1 (%)              **-**

###### 

Toxicity in patients who received Cisplatin consolidation therapy

  Toxicity   Grade 1               Grade 2    Grade 3      Grade 4      Total        
  ---------- --------------------- ---------- ------------ ------------ ------------ ------------
  1\.        Allergic reaction     \-         \-           1 (1.6%)     \-           1 (1.6%)
  2\.        Alopecia              \-         4 (6.6%)     1 (1.6%)     \-           5 (8.2%)
  3\.        Hematologic           4 (6.6%)   11 (18.0%)   4 (6.6%)     \-           19 (31.1%)
             \- Anemia             2 (3.3%)   \-           \-           \-           2 (3.3%)
             \- Leukopenia         3 (4.9%)   10 (16.4%)   \-           \-           13 (21.3%)
             \- Neutropenia        2 (3.3%)   \-           1 (1.6%)     \-           3 (4.9%)
             \- Thrombocytopenia   1 (1.6%)   1 (1.6%)     \-           1 (1.6%)     3 (4.9%)
  4\.        Infection             2 (3.3%)   \-           1 (1.6%)     \-           3 (4.9%)
  5\.        Mucositis             3 (4.9%)   3 (4.9%)     \-           1 (1.6%)     7 (11.5%)
  6\.        Nausea-Vomiting       1 (1.6%)   10 (16.4%)   17 (27.9%)   10 (16.4%)   38 (62.3%)
  7\.        Renal                 4 (6.6%)   \-           \-           \-           4 (6.6%)

###### 

Relapses: isolated or multiple relapses divided by site.

  Site of relapse   Cisplatin (n=61 pts)                                                     Nihil (n=61pts)   
  ----------------- ------------------------------------------------------------------------ ----------------- ------------
                    Total                                                                    36 (59.0%)        30 (49.2%)
  1\.               Peritoneum                                                               15 (24.6%)        10 (16.4%)
  2\.               Retroperitoneum                                                          3 (4.9%)          2 (3.3%)
  3\.               Pelvis                                                                   5 (8.2%)          11 (18%)
  4\.               Lumbo-aortic LN                                                          6 (9.8%)          3 (4.9%)
  5\.               Inguinal LN                                                              5 (8.2%)          1 (1.6%)
  6\.               Supraclavear LN                                                          2 (3.3%)          1 (1.6%)
  7\.               Vaginal dome                                                             1 (1.6%)          5 (8.2%)
  8\.               Spleen                                                                   1 (1.6%)          2 (3.3%)
  9\.               Lung-pleura                                                              5 (8.2%)          6 (9.8%)
  10\.              Liver                                                                    3 (4.9%)          4 (6.6%)
  11\.              CA 125                                                                   5 (8.2%)          1 (1.6%)
  12\.              Bone                                                                     1 (1.6%)          1 (1.6%)
  13\.              Rectum-sigma                                                             1 (1.6%)          1 (1.6%)
  14\.              Ileo-paraintestinal                                                      1 (1.6%)          3 (4.9%)
  15\.              Peritoneum + Pelvis+ Vaginal dome + Rectum-sigma + Ileo-paraintestinal   23 (37.7%)        30 (49.2%)
  16\.              Retroperitoneum + Lumbo-aortic LN + Inguinal LN + Supraclavear LN        16 (26.2%)        7 (11.5%)

LN = lymph node
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